|
|
Article: Acambis: Just One Part Of New Vaccine Development.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Contributing Writer
WASHINGTON - On the same day Acambis plc announced that it had suspended trials for its lead smallpox vaccine, Thomas Monath, the company's chief scientific officer at its facility in Cambridge, Mass., described breakthroughs in new vaccine development.
Monath, speaking Tuesday at the State of the Art in Biodefense Vaccines and Therapeutics symposium in Washington, described the smallpox vaccine as an improvement to the old Dryvax smallpox vaccine. He said the company is still pursuing the fulfillment of a stockpile of 209 million doses for the U.S. government.
But that smallpox vaccine does not represent Acambis' ...
Related newspaper, magazine, and journal articles:
|
|
Article: Recent developments in West Nile virus vaccine ...
Virus Weekly;
October 7, 2003 ;
591 words
... ... Therapeutic Patents. "West Nile virus (WNV ... and patents for vaccine development against WNV infections ... developments in West Nile virus vaccine ... subject areas of West Nile Virus, Mosquito-Borne Disease, Vaccine Development, Vectors and ...
|
|